Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

KYMR stock hub

Kymera Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

KYMRis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

7.1B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

KYMR

In the news

Latest news · KYMR

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-27.1

P25 -105.6P50 -46.5P75 -3.1

ROIC-17.8

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All KYMR market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

203

Groups with data

Currency

USD

Showing 203 of 203 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001815442
Company name	Kymera Therapeutics, Inc.
Country	United States
Country code	US
Cusip	501575104
Employees	253
Employees Change	45%
Employees Change Percent	21.63
Enterprise value	$5.6B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2020-08-21
Isin	US5015751044
Last refreshed	2026-05-10
Market cap	$7.1B
Market cap category	Mid-Cap
Price	$86.08
Price currency	USD
Rev Per Employee	203,462.45x
Sector	Healthcare
Sic	2836
Symbol	KYMR
Website	https://www.kymeratx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-4.45%
EV Sales Forward	84.04x
EV/Sales	109.09x
FCF yield	-3.45%
P/B ratio	4.59x
P/S ratio	137.55x
PS Forward	105.97x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-283M
Net Income	$-315M
Net Income Growth Years	0%
Pretax Margin	-611.94%
Profit Per Employee	$-1.2M
ROA	-17.16
Roa5y	-16.45
ROCE	-22.12
ROE	-27.09
Roe5y	-30.99
ROIC	-17.82

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	195.93%
Cagr3y	43.69%
Cagr5y	14.34%
EPS Growth Quarters	1
EPS Growth Years	0
Revenue Growth	-12.58x
Revenue Growth Q	55.5x
Revenue Growth Quarters	1x
Revenue Growth Years	0x
Revenue Growth3 Y	3.32x
Revenue Growth5 Y	0.86x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.04
Assets	$1.7B
Cash	$650.9M
Current Assets	$677.4M
Current Liabilities	$62.6M
Debt	$80.5M
Debt Equity	$0.05
Equity	$1.5B
Interest Coverage	-989.6
Liabilities	$129.4M
Long Term Assets	$991.6M
Long Term Liabilities	$66.7M
Net Cash	$1.5B
Net Cash By Market Cap	$20.69
Net Cash Growth	112.61%
Net Debt Equity	$-0.95
Tangible Book Value	$1.5B
Tangible Book Value Per Share	$18.73
WACC	15.4

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	10.81
Net Working Capital	$-22.4M
Quick ratio	10.39
Working Capital	$614.8M
Working Capital Turnover	$0.1

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-14.8%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	195.71%
200-day SMA	68.16
3Y total return	196.73%
50-day SMA	83.84
50-day SMA vs 200-day SMA	50over200
5Y total return	95.41%
All Time High	103
All Time High Change	-16.43%
All Time High Date	2025-12-08
All Time Low	9.6
All Time Low Change	796.67%
All Time Low Date	2023-11-02
ATR	3.89
Beta	2.06
Beta1y	0.94
Beta2y	1.86
Ch YTD	10.63
High	86.9
High52	103
High52 Date	2025-12-08
High52ch	-16.43%
Low	83.65
Low52	28.06
Low52 Date	2025-05-27
Low52ch	206.77%
Ma50ch	2.68%
Premarket Change Percent	0.38
Premarket Price	$84.95
Premarket Volume	6,288
Price vs 200-day SMA	26.29%
RSI	53.47
RSI Monthly	67.81
RSI Weekly	59.88
Sharpe ratio	1.71x
Sortino ratio	4.62
Total Return	-14.8%
Tr YTD	10.63
Tr1m	1.15%
Tr1w	6.65%
Tr3m	8.15%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	27
Analyst Count Top	9
Analyst Price Target Top	$95.25
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.86
Earnings Revenue Estimate	8,787,792x
Earnings Revenue Estimate Growth	-60.24x
Operating Income	$-355.3M
Operating margin	-690.2
Price target	$108
Price Target Change	$25.06
Price Target Change Top	$10.65

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	55,051,403%
Float Percent	66.93%
Net Borrowing	-1,642,000
Shares Insiders	1.21%
Shares Institutions	81.62%
Shares Out	82,257,588
Shares Qo Q	8.47%
Shares Yo Y	14.8%
Short Float	17.48%
Short Ratio	15.46
Short Shares	11.7

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-305.7M
Average Volume	512,936.8x
Bv Per Share	18.73
CAPEX	$-1.4M
Ch1m	1.15
Ch1w	6.65
Ch1y	195.7
Ch3m	8.15
Ch3y	196.7
Ch5y	95.41
Ch6m	46.74
Change	1.71%
Change From Open	1.5
Close	84.63
Days Gap	0.21
Depreciation Amortization	6,687,000
Dollar Volume	38,401,148.8
Earnings Date	2026-04-30
Earnings Time	bmo
EBIT	$-355.3M
EBITDA	$-348.6M
EPS	$-3.55
F Score	2
FCF	$-244M
FCF EV Yield	-4.35x
FCF Per Share	$-2.97
Financing CF	1,009,224,000
Fiscal Year End	December
Founded	2,015
Investing CF	-712,516,000
Ipr	330.4
Iprfo	145.9
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-30
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	75.71
Ma150ch	13.7%
Ma20	85.71
Ma20ch	0.43%
Net CF	54,127,000
Next Earnings Date	2026-08-10
Open	84.81
Optionable	Yes
Position In Range	74.77
Ppne	83,353,000
Pre Close	84.63
Price Date	2026-05-08
Ptbv Ratio	4.6
Relative Volume	0.87x
Revenue	51,476,000x
SBC By Revenue	119.82x
Share Based Comp	61,678,000
Tr6m	46.74%
Us State	Massachusetts
Volume	446,110
Z Score	18.29

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does KYMR pay a dividend?

Capital-return profile for this ticker.

Performance

KYMR stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns KYMR?

Insider, institutional, and short-interest positioning.

Institutional ownership

+81.6%

Float: +66.9% of shares outstanding

Insider ownership

+1.2%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

KYMR momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

53.5

Neutral momentum band

Price vs 200-day MA

+26.3%

50/200-day relationship not available

Beta (5Y)

2.06

More volatile than the market

Sharpe ratio

1.71

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About KYMR

Hub-level FAQ points readers to the deeper analysis pages.

What is the current KYMR stock rating?

Kymera Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full KYMR analysis?

The full report lives at /stocks/KYMR/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for KYMR?

The latest report frames KYMR around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the KYMR page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.